We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 05, 2021

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Clin. Cancer Res 2021 Sep 10;[EPub Ahead of Print], GV Long, C Robert, MO Butler, F Couture, MS Carlino, S O'Day, V Atkinson, JS Cebon, MP Brown, S Dalle, AG Hill, GT Gibney, S McCune, AM Menzies, C Niu, N Ibrahim, BH Moreno, A Diab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading